蛋白質治療市場規模、佔有率、成長分析（按類型、應用、最終用戶、功能和地區）- 產業預測，2025 年至 2032 年

2023 年蛋白質治療市場規模價值 2,425.8 億美元，預計將從 2024 年的 2,571.3 億美元成長到 2032 年的 4,098.3 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

世界人口老化導致慢性病發病率上升，推動了對有效蛋白質療法的需求，特別是對抗糖尿病、自體免疫疾病和癌症等疾病。與傳統的小分子藥物不同，生技藥品，尤其是單株抗體，因其功效顯著、副作用小、標靶特異性強而越來越受歡迎。蛋白質工程和生物技術的進步進一步加強了這個市場，重點是融合蛋白和雙特異性抗體等下一代生技藥品的創新。此外，使用單株抗體的個人化癌症治療對於精準治療變得越來越重要。此外，由於全球範圍內鼓勵對罕見疾病進行研究的舉措，蛋白質替代療法 (PRT) 受到越來越多的關注，隨著原始生技藥品的專利到期到期，生物學名藥的出現擴大了治療選擇。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

蛋白質治療市場規模（按類型）

• 市場概況
• 單株抗體
• 胰島素
• 融合蛋白
• 人體生長荷爾蒙
• 促紅血球生成素
• 干擾素

蛋白質治療市場規模（按應用）

• 市場概況
• 癌症
• 代謝紊亂
• 免疫系統疾病
• 血液系統疾病
• 癌症
• 荷爾蒙失調
• 遺傳性疾病
• 其他

蛋白質治療市場規模（按最終用戶分類）

• 市場概況
• 製藥公司
• 醫療服務供應商
• 研究組織
• 學術研究所

蛋白質治療市場規模（按功能分類）

• 市場概況
• 疫苗
• 酵素與調節
• 蛋白質診斷

蛋白質治療藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Johnson & Johnson（United States）
• Roche（Switzerland）
• Merck & Co.（United States）
• Pfizer（United States）
• AbbVie（United States）
• Sanofi（France）
• AstraZeneca（United Kingdom）
• Novartis（Switzerland）
• Bristol-Myers Squibb（United States）
• Abbott Laboratories（United States）
• GlaxoSmithKline（United Kingdom）
• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Amgen（United States）
• Gilead Sciences（United States）
• Biogen（United States）
• Bayer（Germany）
• Takeda Pharmaceutical Company（Japan）
• CSL Behring（Australia）
• Teva Pharmaceutical Industries（Israel）

結論和建議

Protein Therapeutics Market size was valued at USD 242.58 billion in 2023 and is poised to grow from USD 257.13 billion in 2024 to USD 409.83 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The rising prevalence of chronic diseases, driven by an ageing global population, is fueling demand for efficient protein therapeutics, particularly to address conditions like diabetes, autoimmune disorders, and cancer. Unlike traditional small-molecule drugs, biologics, especially monoclonal antibodies, are gaining popularity due to their efficacy, fewer side effects, and targeted specificity. Advancements in protein engineering and biotechnology are further enhancing this market, with a focus on innovating next-generation biologics such as fusion proteins and bispecific antibodies. Moreover, tailored cancer therapies utilizing monoclonal antibodies are increasingly vital for precise treatment. In addition, protein replacement therapies (PRTs) are receiving significant attention, spurred by global initiatives encouraging research into rare diseases, alongside the emergence of biosimilars as original biologics' patents expire, broadening therapeutic options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

The Protein Therapeutics market is significantly driven by the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, which are becoming increasingly widespread globally. This surge in chronic illnesses is a primary catalyst for the growing demand for innovative protein-based treatments, such as biologics and monoclonal antibodies. These advanced therapeutic options offer targeted treatment capabilities, allowing for more effective management of complex medical conditions while minimizing side effects. As healthcare providers seek to address these pressing health issues, the reliance on protein therapeutics continues to expand, shaping the future of medical treatments and improving patient outcomes.

Restraints in the Protein Therapeutics Market

Despite the effectiveness of protein therapeutics, several factors hinder their widespread adoption. Chief among these is the high cost associated with these treatments, which renders them inaccessible to numerous patients. Additionally, inadequate insurance coverage complicates the financial landscape, as reimbursement levels vary significantly across different regions. This variability particularly affects patients in emerging markets, where affordability becomes a major barrier. Such economic challenges ultimately restrict market growth, limiting the potential of protein therapeutics to reach those who could benefit most from them, thereby impeding progress in this vital healthcare sector.

Market Trends of the Protein Therapeutics Market

The Protein Therapeutics market is experiencing a significant upward trend, fueled by the rising demand for personalized medicine that tailors treatments to individual genetic profiles. This shift enhances treatment efficacy while minimizing adverse effects, thereby attracting a larger patient base, particularly for oncology and autoimmune disorders. The increased focus on targeted biologics and advanced protein therapies not only caters to the specific needs of patients but also drives innovation in drug development. As healthcare providers embrace personalized approaches, investment in research and technology for protein-based therapeutics will likely intensify, positioning this market for substantial growth and advancement in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Human Growth Hormone
• Erythropoietin
• Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cancer
• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

Global Protein Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical companies
• Healthcare Service Providers
• Research Organizations
• Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2025-2032)

• Market Overview
• Vaccines
• Enzymatic and Regulatory
• Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, End User, Function)
  • US
  • Canada
• Europe (Type, Application, End User, Function)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User, Function)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User, Function)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User, Function)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations